# LataMed AI Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/LataMed AI Corp.). ## Overview LataMed AI Corp. is a U.S.-based healthcare technology company focused on artificial intelligence-enabled analytics, telehealth infrastructure, and healthcare services coordination. The company’s operating structure includes a wholly owned Venezuelan subsidiary intended to support its Latin American healthcare technology and services platform. ## Products & services • AI-enabled healthcare analytics platform • Technology-enabled healthcare services coordination • Patient monitoring applications • Telehealth infrastructure solutions • Healthcare data and regulatory planning support - **Healthcare AI analytics** (40%) — Software and data tools for healthcare analytics, monitoring, and decision support. - **Telehealth infrastructure** (25%) — Technology used to support remote care delivery and virtual healthcare workflows. - **Care coordination services** (20%) — Services that organize patient pathways, referrals, and healthcare service delivery. - **Healthcare technology IP** (15%) — Proprietary assets and intellectual property acquired for platform development. - AI-enabled healthcare analytics platform - Technology-enabled healthcare services coordination - Patient monitoring applications - Telehealth infrastructure solutions - Healthcare data and regulatory planning support ## Customers The company appears to serve healthcare organizations and service providers that need software and operational tools for analytics, telehealth, and patient coordination. Its Latin America focus suggests customers may also include regional healthcare operators and partners seeking localized digital health infrastructure. Because the business is still in an early operating build-out phase, customer relationships are likely centered on platform adoption, pilot deployments, and business development rather than broad-scale recurring usage. - **Healthcare providers** (primary) — Hospitals, clinics, and care networks that would use analytics, monitoring, and telehealth tools to improve care delivery. - **Healthcare service operators** (primary) — Organizations coordinating patient services and workflows that need software to manage care pathways and communications. - **Latin American healthcare partners** (secondary) — Regional operators and counterparties in Latin America that may adopt localized healthcare technology and services. - **Telehealth users and platforms** (secondary) — Customers needing virtual care infrastructure and related digital health applications. - Healthcare providers needing analytics and patient monitoring tools - Telehealth operators requiring digital care infrastructure - Regional healthcare service partners in Latin America - Organizations seeking care coordination and workflow software - Potential public or private health system partners ## Geography LataMed AI Corp. is incorporated in the United States, but its stated operating focus is Latin America. The company has also organized a Venezuelan subsidiary to serve as an operating entity and to support its broader regional strategy. This geographic mix creates exposure to cross-border execution, local regulatory requirements, and country-specific operating conditions in Latin America. - Headquartered in the United States - Operating focus on Latin America - Venezuelan subsidiary supports regional execution - Cross-border healthcare technology deployment - Local regulatory planning is important to market entry ## Strategy The company is transitioning toward an AI-enabled healthcare technology and services model centered on Latin America. Its near-term priorities appear to be integrating acquired healthcare technology assets, building operating infrastructure, and advancing regulatory and business development work needed to commercialize the platform. Financing remains a strategic requirement because the business is still in development and has not yet established a revenue base. - **Commercialize the healthcare AI platform** (short-term) — The company needs a marketable product and service offering to convert development work into revenue. - **Build Latin American operating infrastructure** (short-term) — Regional execution depends on local operating entities, regulatory readiness, and market relationships. - **Integrate acquired proprietary assets** (medium-term) — The acquired IP and technology assets are the core inputs for the company’s platform strategy. - **Raise external capital** (short-term) — A development-stage healthcare technology business typically requires funding before scale is reached. - Develop AI-enabled healthcare platform and services stack - Integrate acquired healthcare technology assets and IP - Build Venezuelan operating capability for Latin America - Advance regulatory and market-entry planning - Secure external financing to support operations ## Risks The company faces early-stage execution and financing risk because it is still building its healthcare technology platform and has not yet established meaningful revenue. Its Latin America strategy adds regulatory, operational, and cross-border complexity, while the use of acquired intellectual property introduces integration and valuation risk. As with many development-stage software and healthcare services businesses, success depends on product adoption, capital access, and the ability to navigate healthcare-specific compliance requirements. - **Insufficient liquidity and financing risk** [critical] — The company states it does not have sufficient cash to operate at the current level for the next twelve months. - **Early-stage commercialization risk** [high] — The business is still in organizational development and has not generated revenue, so product-market fit is unproven. - **Cross-border regulatory risk** [high] — Operating in Latin America, including Venezuela, can involve local healthcare, data, and corporate compliance requirements. - **Integration risk for acquired assets** [medium] — The company acquired proprietary healthcare technology assets and must integrate them into its operating model. - No revenue base increases dependence on funding and execution - Additional capital may be difficult to raise on acceptable terms - Latin America expansion adds regulatory and operational complexity - Acquired IP may not integrate as expected or create value - Healthcare technology adoption can be slow and relationship-driven ## Accounting Revenue recognition under ASC 606 is important because the company’s contracts may involve software, services, and coordination deliverables that can have different performance obligations. The company also relies on estimates and fair value judgments, especially around acquired intangible assets, stock-based compensation, and any future impairment testing. Because the business is early-stage and has no revenue, professional fees, financing costs, and asset valuation judgments can materially affect reported losses and balance sheet values. - **Revenue recognition under ASC 606** — Affects when and how contract revenue is recorded - **Intangible asset valuation and impairment** — Could create impairment charges if expected value is not realized - **Fair value measurements** — Can affect balance sheet carrying values and expense recognition - **Stock-based compensation** — Can materially increase reported operating expenses - ASC 606 revenue recognition depends on contract performance obligations - Acquired intangible assets may require impairment testing under ASC 350 - Fair value estimates affect valuation of financial instruments and assets - Stock-based compensation can affect operating expense and equity - Use of estimates is important in a development-stage company --- *Last updated: 2026-06-16T23:00:45.953766+00:00*